Hideho Okada, MD, PhD
|School||UCSF School of Medicine|
|Address||1450 3rd Street|
San Francisco CA 94158
|Nagoya University ||M.D.||1991||School of Medicine|
|Nagoya University ||Ph.D.||1996||School of Medicine|
|Uehara Memorial Foundation ||1996
|Doris Duke Charitable Foundation ||2001
||2006||Clinical Scientist Development Award|
|James S. McDonnell’s Foundation||2003
||2007||21st Century Scientist Award|
|Journal of Translational Medicine||2006
||2007||Excellence in Translational Medicine Award |
|University of Pittsburgh ||2008||Innovator Award |
|University of Pittsburgh||2009||Faculty Honoree at the Annual Convocation |
|American Society for Clinical Investigation (ASCI)||2010||Selected to be a Member|
|Society for Immunotherapy for Cancer ||2010||Team Science Recognition Award |
|University of Pittsburgh||2011||Faculty Honoree at the Annual Convocation |
|University of Pittsburgh ||2012||Innovator Award |
|University of Pittsburgh||2013||Faculty Honoree at the Annual Convocation |
|University of Pittsburgh||2014||Faculty Honoree at the Annual Convocation|
Dr. Okada is a creative physician-scientist who has developed therapeutic modalities in the laboratory, translated them into clinical protocols, and used his expertise as both scientist and clinician to assess the clinical data from ongoing trials. Dr. Okada's work has consistently focused on immunotherapeutic strategies aimed at a daunting challenge in oncology – malignant brain tumors. Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. Dr. Okada's success in navigating the detailed regulatory processes that such trials require demonstrates his attention to detail and breadth of knowledge from basic science to clinical care. Dr. Okada's lab work was the first to identify and fully characterize cytotoxic T-lymphocyte (CTL) epitopes for gliomas. Dr. Okada's seminal discovery of CTL epitopes in glioma-associated antigens and the work on the mechanisms underlying the adjuvant effects of poly-ICLC enabled him to launch novel glioma vaccine trials in combination with poly-ICLC as an adjuvant. These efforts have also been supported by his mechanistic studies delineating the role of an integrin receptor very late activation antigen (VLA)-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has held 4 Investigational New Drug approvals for his own vaccine trials. Since 2004 to 2014, Dr. Okada served as a Co-Leader of the Brain Tumor Program within the University of Pittsburgh Cancer Institute and has worked to expand the program by developing strong interdisciplinary and translational research activities among program members. In 2010, Dr. Okada was selected to be a member of the American Society for Clinical Investigation, which is an honor society of physician-scientists, those who translate findings in the laboratory to the advancement of clinical practice.
, adoptive transfer
, dendritic cell
, myeloid cell
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share related concepts with this person.